The strategy discussed here can be considered as an important step in developing pan-incretins against SARS-CoV-2 mutations, long-COVID symptoms and other neurological diseases such as multiple sclerosis [84,126,127,128,129,130]. This evidence concerns the gene GCG and nervous system disorder.